A Phase 4 interventional study of Tildrakizumab in Psoriasis Vulgaris, sponsored by University of California, San Francisco. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-30.
Sponsored by University of California, San Francisco · Phase 4, Interventional, and Basic science
This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.
This is a one-arm, open-label study to examine the effect of Tildrakizumab. Tildrakizumab is a FDA-approved medication for the treatment of cutaneous psoriasis. This study will examine how Tildrakizumab affects immune cells within psoriatic skin lesions. Fifteen subjects with moderate to severe psoriasis will be enrolled. Biopsy samples will be collected and undergo molecular profiling to correlate profiles with and to predict Tildrakizumab treatment response.
1,899 studies on the registry are indexed under Psoriasis; 233 are open to participants now.
This study's enrollment of 7 is below the median of 70 across 1,447 interventional studies indexed under Psoriasis.
Browse Psoriasis studies →University of California, San Francisco is the lead sponsor of 2,132 studies on the registry; 375 are open to participants now.
Of its 262 completed or terminated interventional studies of FDA-regulated products, 196 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Biological: Tildrakizumab
IL-23 inhibitor
Psoriasis Area and Severity Index (PASI) Score
Psoriasis Area and Severity Index (PASI) is a measure of psoriasis severity. The maximum score is 72, minimum score is 0. The higher the number, the more severe the psoriasis is.
Time frame: baseline and 3 months
| Milestone | Tildrakizumab Treatment |
|---|---|
| Started | 7 |
| Completed | 7 |
| Not completed | 0 |
Psoriasis Area and Severity Index (PASI) is a measure of psoriasis severity. The maximum score is 72, minimum score is 0. The higher the number, the more severe the psoriasis is.
| score on a scale | Tildrakizumab Treatment |
|---|---|
| Psoriasis Area and Severity Index (PASI) Score | 3.9 ± 4.1 |
Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tildrakizumab Treatment | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
| Age, Categorical(Participants) | Tildrakizumab Treatment |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 7 |
| >=65 years | 0 |
| Age, Continuous(years) | Tildrakizumab Treatment |
|---|---|
| Mean | 37 (30 to 46) |
| Sex: Female, Male(Participants) | Tildrakizumab Treatment |
|---|---|
| Female | 3 |
| Male | 4 |
| Race and Ethnicity Not Collected(Participants) | Tildrakizumab Treatment |
|---|
| Region of Enrollment(Participants) | Tildrakizumab Treatment |
|---|---|
| United States | 7 |
| Psoriasis Area and Severity Index (PASI) Score(units on a scale) | Tildrakizumab Treatment |
|---|---|
| Mean | 10.7 ± 3.6 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco